Gefitinib, the first generation of EGFR TKIs, was approved by Food and Drug Administration (FDA) in 2003 as the second line drug for the treatment of patients with advanced NSCLC after failure of both platinum-based and docetaxel therapies [33]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.